Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Mouse LIF ELISA Kit (AC3224)
Cat.#: ASET-1813
Specifications
Description Mouse LIF ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of mouse LIF concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Mouse Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.046 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 1.5-24 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1367 Porcine Syndecan-1 ELISA Kit (AC2778) Quantitative inquiry ASET-1124 Human SOX3 ELISA Kit (AC2535) Quantitative inquiry ASET-2521 Human RKIP ELISA Kit (AC3932) Quantitative inquiry ASET-1122 Rat CX3CR1 ELISA Kit (AC2533) Quantitative inquiry ASET-1932 Human ADAM17 ELISA Kit (AC3343) Quantitative inquiry ASET-1126 Human Otoraplin ELISA Kit (AC2537) Quantitative inquiry ASET-1412 Human UNC5D ELISA Kit (AC2823) Quantitative inquiry ASET-1928 Human VEGFC ELISA Kit (AC3339) Quantitative inquiry ASET-1953 Human Enkephalin ELISA Kit (AC3364) Quantitative inquiry ASET-2429 Human PPAR gamma ELISA Kit (AC3840) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket